{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:54:06Z","timestamp":1790790846571,"version":"4.1.0"},"reference-count":28,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"unspecified","delay-in-days":40,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,4,5]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The phase III SELECT-MONOTHERAPY trial (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02706951\">NCT02706951<\/jats:ext-link>) demonstrated the safety and efficacy of upadacitinib (UPA) monotherapy through 84 weeks in patients with rheumatoid arthritis who responded inadequately to methotrexate. Here we report week 260 results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients were randomised to continue methotrexate or UPA 15 mg (UPA15) or 30 mg (UPA30) monotherapy for 14 weeks. From week 14, patients continuing methotrexate switched to UPA15 or UPA30 per prespecified assignment; patients randomised to UPA continued treatment. Following a protocol amendment, all cohorts switched to open-label UPA15. Safety was summarised using exposure-adjusted event and incidence rates. Efficacy was reported as observed and using non-responder imputation (NRI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 648 randomised patients, 598 entered the long-term extension. Of these, 249 (41.6%) discontinued study drug by week 260 primarily due to adverse events (14.5%), consent withdrawal (9.9%), lost to follow-up (3.3%), lack of efficacy (2.2%), COVID-19 (0.7%) or other reasons (11.0%). Rates of herpes zoster, non-melanoma skin cancer, hepatic disorder, neutropenia, lymphopenia and creatine kinase elevation were higher with UPA30 versus UPA15. Long-term UPA safety data were consistent with the established UPA safety profile. Based on NRI, &gt;39% of patients treated continuously with UPA achieved low disease activity per Clinical Disease Activity Index \u226410 (UPA15, n=93\/217; UPA30, n=91\/215) and 28-joint Disease Activity Score using C reactive protein \u22643.2 (UPA15, n=90\/217; UPA30, n=94\/215) at week 260. Efficacy was similar among patients switching from methotrexate to UPA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>No new safety risks were identified with long-term UPA treatment. UPA monotherapy was efficacious in treating rheumatoid arthritis through week 260.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02706951\">NCT02706951<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-005051","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T07:45:18Z","timestamp":1746949518000},"page":"e005051","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02706951","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02706951","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02706951","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02706951","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Josef S","family":"Smolen","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8482","authenticated-orcid":false,"given":"Paul","family":"Emery","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Biomedical Research Centre, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Rigby","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Dartmouth Health, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ignacio","family":"Vargas","sequence":"additional","affiliation":[{"name":"Quantum Research, Puerto Varas, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Jain","sequence":"additional","affiliation":[{"name":"Flourish Research, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle M","family":"Carter","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Khan","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Phillips","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Meerwein","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley B","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,11]]},"reference":[{"key":"2025090313565185000_11.2.e005051.1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S219586"},{"key":"2025090313565185000_11.2.e005051.2","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090313565185000_11.2.e005051.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2025090313565185000_11.2.e005051.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61000-4"},{"key":"2025090313565185000_11.2.e005051.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066662"},{"key":"2025090313565185000_11.2.e005051.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2003.12.003"},{"key":"2025090313565185000_11.2.e005051.7","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/1756-185X.14207","article-title":"Assessing methotrexate intolerance and its prevalence in rheumatoid arthritis: Development and validation of the MISA questionnaire","volume":"24","author":"Vijaykumar","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"2025090313565185000_11.2.e005051.8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s42358-020-00145-5","article-title":"High frequency of methotrexate intolerance in longstanding rheumatoid arthritis: using the methotrexate intolerance severity score (MISS)","volume":"60","author":"Amaral","year":"2020","journal-title":"Adv Rheumatol"},{"key":"2025090313565185000_11.2.e005051.9","doi-asserted-by":"crossref","DOI":"10.1186\/ar4413","article-title":"Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis","volume":"15","author":"\u0106alasan","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2025090313565185000_11.2.e005051.10","unstructured":"RINVOQ (upadacitinib) . Summary of product characteristics. AbbVie Inc. 2024. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rinvoq-epar-product-information_en.pdf [Accessed 19 Jun 2024]."},{"key":"2025090313565185000_11.2.e005051.11","unstructured":"RINVOQ (upadacitinib) . Prescribing information. AbbVie GK Tokyo. 2023. Available: https:\/\/a-connect.abbvie.co.jp\/-\/media\/assets\/pdf\/products\/rinvoq\/Rinvoq_tmpDocument.pdf [Accessed 20 Feb 2025]."},{"key":"2025090313565185000_11.2.e005051.12","unstructured":"RINVOQ (upadacitinib) . Prescribing information. AbbVie Inc. 2023. Available: https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf [Accessed 01 Feb 2024]."},{"key":"2025090313565185000_11.2.e005051.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2"},{"key":"2025090313565185000_11.2.e005051.14","doi-asserted-by":"crossref","unstructured":"Smolen JS , Emery P , Rigby W , et al . Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 84 weeks [abstract]. Ann Rheum Dis 2020;72. Available: https:\/\/acrabstracts.org\/abstract\/upadacitinib-as-monotherapy-in-patients-with-rheumatoid-arthritis-and-prior-inadequate-response-to-methotrexate-results-at-84-weeks\/","DOI":"10.1136\/annrheumdis-2020-eular.961"},{"key":"2025090313565185000_11.2.e005051.15","first-page":"1401","article-title":"Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0","volume":"34","author":"Woodworth","year":"2007","journal-title":"J Rheumatol"},{"key":"2025090313565185000_11.2.e005051.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.30129"},{"key":"2025090313565185000_11.2.e005051.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223413"},{"key":"2025090313565185000_11.2.e005051.18","first-page":"557","article-title":"Minimum important difference between patients with rheumatoid arthritis: the patient\u2019s perspective","volume":"20","author":"Wells","year":"1993","journal-title":"J Rheumatol"},{"key":"2025090313565185000_11.2.e005051.19","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"2025090313565185000_11.2.e005051.20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40744-023-00621-6","article-title":"Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis","volume":"11","author":"Rubbert-Roth","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2025090313565185000_11.2.e005051.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"2025090313565185000_11.2.e005051.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"2025090313565185000_11.2.e005051.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218398"},{"key":"2025090313565185000_11.2.e005051.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"2025090313565185000_11.2.e005051.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223636"},{"key":"2025090313565185000_11.2.e005051.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"2025090313565185000_11.2.e005051.27","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1093\/rheumatology\/keaa770","article-title":"Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY","volume":"60","author":"Strand","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313565185000_11.2.e005051.28","first-page":"723","article-title":"POS0847 UPADACITINIB as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the select-monotherapy study","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-005051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:56:58Z","timestamp":1756933018000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-005051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,5,11]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/rmdopen-2024-005051"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-005051","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}